STOCK TITAN
  1. Home
  2. News
  3. CLLS

Cellectis S.A. American Depositary Shares - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.

Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.

Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.

Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.

Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.

For more information, visit the company's website at www.cellectis.com.

News

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) to hold a general meeting on December 22, 2023, at 2:30 p.m. CET at the Biopark auditorium in Paris, France. The notice of meeting, agenda, resolutions, and terms of participation are available on the Cellectis website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none
-
News

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) has signed a binding Subsequent Investment Agreement with AstraZeneca regarding the additional equity investment of $140M previously announced. AstraZeneca will subscribe to 10,000,000 'class A' convertible preferred shares and 18,000,000 'class B' convertible preferred shares at $5.00 per share. The approval of an extraordinary shareholders’ meeting of Cellectis and clearance from the French Ministry of Economy are required before the closing of the investment, which is expected to result in AstraZeneca owning approximately 44% of the share capital and 30% of the voting rights of Cellectis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
-
News

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has signed strategic collaboration and investment agreements with AstraZeneca. The collaboration will leverage Cellectis' gene editing technologies to develop next-generation therapeutics in areas of high unmet need. Cellectis' clinical-stage assets will remain under its ownership. The company also provided updates on its clinical trials and preclinical programs, including the BALLI-01 trial evaluating UCART22 and the NATHALI-01 trial evaluating UCART20x22. Cellectis has a cash position of $721 million as of September 30, 2023, providing a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.41%
Tags
earnings
News

Monthly information on share capital and company voting rights

Rhea-AI Summary
Cellectis, a company listed on Euronext Growth, has a total of 55,583,768 shares in its capital and 61,519,396 voting rights as of October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
none
-
News

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Rhea-AI Summary
Cellectis announced that preliminary results of the Phase I NATHALI-01 clinical trial and updated results of the Phase I BALLI-01 clinical trial will be presented at the ASH 2023. The data shows positive responses in patients with relapsed or refractory non-Hodgkin lymphoma and CD22+ B-cell acute lymphoblastic leukemia. No dose limiting toxicities were observed, and the studies continue to enroll patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences
-
News

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, will report financial results for Q3 2023 on November 6, 2023. An investor conference call and webcast will be held on November 7, 2023, providing an update on business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.02%
Tags
conferences earnings
News

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Rhea-AI Summary
Cellectis has entered into a collaboration agreement, investment agreement, and memorandum of understanding with AstraZeneca. AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell and gene therapy candidate products. Cellectis will receive up to $245M in cash, including an upfront payment of $25M and potential milestone payments and royalties. AstraZeneca will make an initial equity investment of $80M and a potential additional investment of $140M. Cellectis' clinical-stage assets will remain under its ownership and control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
172.16%
Tags
none
-
News

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on MUC1-CAR T-cells at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data demonstrates the enhanced activity and reduced off-tumor toxicity of the cells when combined with ΔPD1-IL12 and TGFBR2-KO attributes in preclinical models of triple negative breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
172.16%
Tags
clinical trial
-
News

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Rhea-AI Summary
Cellectis to showcase pre-clinical data on gene therapy program at ESGCT congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences clinical trial
News

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Rhea-AI Summary
Cellectis announces new research paper demonstrating gene correction efficacy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none

FAQ

What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?

The current stock price of Cellectis S.A. American Depositary Shares (CLLS) is $1.64 as of December 20, 2024.

What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?

The market cap of Cellectis S.A. American Depositary Shares (CLLS) is approximately 154.1M.

What does Cellectis S.A. specialize in?

Cellectis S.A. specializes in developing cancer immunotherapies using gene-edited T-cells, known as UCART.

What proprietary technologies does Cellectis use?

Cellectis uses its proprietary TALEN® technology and PulseAgile electroporation system for gene editing.

What are UCART cells?

UCART cells are allogeneic Chimeric Antigen Receptor T-cells developed to target and eradicate cancer cells.

What recent advancements has Cellectis made?

Cellectis has introduced a novel method for circularizing non-viral single-strand DNA templates to enhance gene editing outcomes in HSPCs.

Which companies has Cellectis partnered with?

Cellectis has partnership agreements with companies like AstraZeneca, expanding its pipeline of allogeneic CAR T-cell therapies.

On which stock markets is Cellectis listed?

Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets.

What are HSPCs?

HSPCs are hematopoietic stem and progenitor cells, which Cellectis gene-edits for various therapeutic applications.

How long has Cellectis been in the gene editing field?

Cellectis has over 18 years of expertise in the gene editing field.

Where can I find more information about Cellectis?

More information about Cellectis can be found on their website at www.cellectis.com.

How does Cellectis contribute to immuno-oncology?

Cellectis develops innovative immuno-oncology therapies by harnessing the power of gene-edited T-cells to fight cancer.

Stock CLLS logo
Cellectis S.A. American Depositary Shares

Nasdaq:CLLS

CLLS Rankings

#4087 Ranked by Market Cap
N/A Ranked by Dividends

CLLS Stock Data

154.14M
93.36M
3.87%
16.65%
0.14%
Biotechnology
Healthcare
Link
United States of America
Paris